Strategic foresight and global impact: SGD Pharma at CPHI Frankfurt 2025

Strategic foresight and global impact: SGD Pharma at CPHI Frankfurt 2025 🌍

At SGD Pharma, our strategy is clear: contribute to shaping the future of pharmaceutical packaging through High Quality, Excellent Service to our customers, Operational excellence and Innovation, in a sustainable way, and purposeful growth, always with patient safety at the heart of everything we do.

🎙 Olivier Rousseau, our CEO, shares his vision:

“We are focused on delivering long-term value for our customers and accelerate toward a more resilient and sustainable healthcare ecosystem. Quality and Service have always been at the heart of what we do to protect and improve patients’ lives. We are leading Molded Pharma Glass Packaging and are developing our Tubular Pharma Glass business.
The recent acquisition of Alphial is another key milestone in this journey.”

At CPHI Frankfurt, discover how our strategic roadmap is already delivering impact:

✅ Global leadership, local proximity: With operations across three continents, we ensure agility, capacity, and reactivity, wherever our customers operate.
✅ Investment in excellence: From advanced lab services to manufacturing modernization, we are committed to continuous improvement at scale.
✅ Sustainable transformation: Our path to carbon neutrality is accelerating, with concrete results and certified progress. With a 42% CO₂ emissions reduction targeted by 2030 and 65% by 2040 (vs. 2022), our ambition is matched by action.
✅ Innovation with purpose: Every new product, service or partnership we launch is designed to answer a customer or a patient need, shaping safer, faster, more sustainable therapies.

Ready to talk about strategy, growth and of how we can help you?
Join Olivier Rousseau and the SGD Pharma leadership team at booth 8.0H24 (and 8.0G1 for Alphial).